BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pelacarsen readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Pelacarsen\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06813911-1038@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20280203
DTEND;VALUE=DATE:20280204
SUMMARY:Pelacarsen: Phase 3 readout est. (NCT06813911)
DESCRIPTION:Pelacarsen\, phase 3\, Atherosclerotic Cardiovascular Disease.\
 nStudy: Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclis
 iran in Participants With Elevated Lp(a) and Established ASCVD\nEstimated 
 primary completion: 3 February 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/pelacarsen#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06813911
URL:https://assetmemo.bio/drug/pelacarsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07517263-1038@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20300109
DTEND;VALUE=DATE:20300110
SUMMARY:Pelacarsen: Phase 3 readout est. (NCT07517263)
DESCRIPTION:Pelacarsen\, phase 3\, Atherosclerotic Cardiovascular Disease.\
 nStudy: An Open Label Extension (OLE) Study (Following Completion of CTQJ2
 30A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ
 230)\nEstimated primary completion: 9 January 2030. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/pelacarsen#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07517263
URL:https://assetmemo.bio/drug/pelacarsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05646381-1038@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20300312
DTEND;VALUE=DATE:20300313
SUMMARY:Pelacarsen: Phase 2 readout est. (NCT05646381)
DESCRIPTION:Pelacarsen\, phase 2\, Atherosclerotic Cardiovascular Disease.\
 nStudy: A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowerin
 g With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Ste
 nosis\nEstimated primary completion: 12 March 2030. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/pelacarsen#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05646381
URL:https://assetmemo.bio/drug/pelacarsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06875973-1038@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20301208
DTEND;VALUE=DATE:20301209
SUMMARY:Pelacarsen: Phase 3 readout est. (NCT06875973)
DESCRIPTION:Pelacarsen\, phase 3\, Atherosclerotic Cardiovascular Disease.\
 nStudy: Pelacarsen Roll-over Extension Program\nEstimated primary completi
 on: 8 December 2030. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 pelacarsen#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06875973
URL:https://assetmemo.bio/drug/pelacarsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
